NASDAQ$SCPX
Scorpius Holdings Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Heat Biologics reported a net loss for the second quarter of 2021, while making progress in clinical, research, and business milestones.
Heat Biologics reported a net loss of $6.5 million, or ($0.26) per share, for the quarter ended June 30, 2021. The company had $122.5 million in cash, cash equivalents and short investments as of June 30, 2021. They recognized $0.5 million of grant revenue.
- Presented favorable survival data of HS-110 in NSCLC patients at ASCO 2021.
- Evaluating possible Phase 3 registration pathways with the FDA and potential partners for HS-110.
- Announced the groundbreaking for a biomanufacturing/bioanalytic facility in San Antonio, TX and the expansion of R&D facilities in Morrisville, NC.
- Maintained a strong balance sheet with approximately $122.5 million of cash, cash equivalents and short-term investments.
Headline financials
Revenue & EPS history
Scorpius Holdings · Revenue · Quarterly
$459K
Revenue by segment
Scorpius Holdings · $459K total across 1 segment · Q2 2021
- Grant and Contract Revenue$459K—100.0%
Forward guidance
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events.
Tailwinds
- HS-110, in combination with a checkpoint inhibitor (CPI), holds significant potential to improve survival benefit for patients with non-small cell lung cancer
- Heat's vaccine platform can provide prevention and treatment of cancer and infectious diseases, such as COVID-19
- Heat can accelerate R&D timelines and generate cost savings on research and development by bringing more of its development activities in-house
- Heat can augment its clinical programs and enhance and expand its therapeutic pipeline
- Heat’s cash and short-term investments provide significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio
Headwinds
- The ability of HS-110, in combination with a checkpoint inhibitor (CPI), holds significant potential to improve survival benefit for patients with non-small cell lung cancer
- The ability of Heat's vaccine platform to provide prevention and treatment of cancer and infectious diseases, such as COVID-19
- Heat's ability to accelerate R&D timelines and generate cost savings on research and development by bringing more of its development activities in-house
- Heat's ability to augment its clinical programs and enhance and expand its therapeutic pipeline
- Heat's ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.3%
Avg return
Earnings day
+100.8%
Avg return
5 days after
+129.2%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+5.2%
Q1 2021
Best reaction
-9.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +1350.0% | +3100.0% | |
| Q2 2025 | +0.0% | +900.0% | -60.0% | |
| Q1 2025 | -1.4% | +0.7% | +4.1% | |
| Q4 2024 | +0.0% | -1.5% | -2.9% | |
| Q1 2026 | +2.8% | -41.4% | -41.1% | |
| Q1 2024 | +2.8% | -41.4% | -41.1% | |
| Q3 2024 | +3.5% | +12.6% | -35.6% | |
| Q4 2023 | +0.0% | +2.1% | -19.1% | |
| Q3 2023 | -0.8% | -13.7% | -34.5% | |
| Q2 2023 | -1.6% | -12.9% | -2.9% | |
| Q1 2023 | -0.0% | -4.0% | -24.6% | |
| Q4 2022 | -0.0% | -4.0% | -24.6% | |
| Q3 2022 | +2.3% | -4.4% | -33.6% | |
| Q2 2022 | +0.4% | -11.5% | -22.2% | |
| Q1 2022 | -1.0% | -5.8% | -23.3% | |
| Q4 2021 | -9.4% | +12.4% | +17.9% | |
| Q3 2021 | -2.5% | -7.2% | -21.6% | |
| Q2 2021 | +1.2% | -4.3% | -4.1% | |
| Q1 2021 | +5.2% | +6.2% | -0.7% | |
| Q4 2020 | +1.8% | -8.9% | -10.3% | |
| Q3 2020 | -9.6% | -7.0% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro